Skip to main content
Journal cover image

Androgen deprivation therapy and cardiovascular disease.

Publication ,  Journal Article
Melloni, C; Roe, MT
Published in: Urol Oncol
February 2020

Prostate cancer (PCa) is the most common cancer among men. Advances in early detection and successful treatments have improved cancer-specific survival. With prolonged survival, PCa patients now suffer from the effects of aging and are at increasing risk for the development of cardiovascular (CV) risk factors and CV disease. Androgen deprivation therapy (ADT) is the mainstay treatment of advanced PCa. There is conflicting evidence about whether or not ADT is associated with increased CV morbidity and mortality. Metabolic abnormalities such as increasing body weight, reduced insulin sensitivity, dyslipidemia, and activation of T cells to the Th1 phenotype, resulting in atherosclerotic plaque destabilization, have been proposed as possible mechanisms by which ADT may increase the risk of CV events. Type of ADT and preexisting CV history also seem to play a major role in the risk of subsequent CV events. Ongoing prospective clinical trials will help define whether there is any difference between gonadotropin-releasing hormone agonists and antagonists in terms of CV morbidity and mortality.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Urol Oncol

DOI

EISSN

1873-2496

Publication Date

February 2020

Volume

38

Issue

2

Start / End Page

45 / 52

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Prostatic Neoplasms
  • Male
  • Humans
  • Cardiovascular Diseases
  • Androgen Antagonists
  • Aged
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Melloni, C., & Roe, M. T. (2020). Androgen deprivation therapy and cardiovascular disease. Urol Oncol, 38(2), 45–52. https://doi.org/10.1016/j.urolonc.2019.02.010
Melloni, Chiara, and Matthew T. Roe. “Androgen deprivation therapy and cardiovascular disease.Urol Oncol 38, no. 2 (February 2020): 45–52. https://doi.org/10.1016/j.urolonc.2019.02.010.
Melloni C, Roe MT. Androgen deprivation therapy and cardiovascular disease. Urol Oncol. 2020 Feb;38(2):45–52.
Melloni, Chiara, and Matthew T. Roe. “Androgen deprivation therapy and cardiovascular disease.Urol Oncol, vol. 38, no. 2, Feb. 2020, pp. 45–52. Pubmed, doi:10.1016/j.urolonc.2019.02.010.
Melloni C, Roe MT. Androgen deprivation therapy and cardiovascular disease. Urol Oncol. 2020 Feb;38(2):45–52.
Journal cover image

Published In

Urol Oncol

DOI

EISSN

1873-2496

Publication Date

February 2020

Volume

38

Issue

2

Start / End Page

45 / 52

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • Prostatic Neoplasms
  • Male
  • Humans
  • Cardiovascular Diseases
  • Androgen Antagonists
  • Aged
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis